<b><i>Introduction:</i></b> Haemato-oncologic patients are more susceptible to severe infections with SARS-CoV-2. We aimed to assess the clinical outcomes of SARS-CoV-2 infection among patients with Mycosis Fungoides and Sezary Syndrome (MF/SS). <b><i>Methods:</i></b> The data were retrieved from anonymized electronic medical records of Maccabi Healthcare Services (MHS), the second-largest healthcare organization in Israel. Patients diagnosed with MF/SS were included in the study. COVID-19 PCR test results together with sociodemographic and clinical data were extracted and analyzed to evaluate the association of COVID-19 with clinical outcomes. <b><i>Results:</i></b> In the period of 2020–2022, 1,472 MF/SS patients were included in the study. Among them, 768 (52%) had SARS-CoV-2 infection. The hospitalization rate was 2.9% and infection by the Delta variant was associated with the highest hospitalization rate (7.7%). The hospitalization rate was lower among fully vaccinated patients (<i>p</i> = 0.032) but higher for patients older than 65 (<i>p</i> &lt; 0.001) and patients with SS (vs. MF) (<i>p</i> &lt; 0.001) or COPD (<i>p</i> = 0.024) diagnosis. There was a tendency for decreased hospitalization among patients treated with nirmatrelvir + ritonavir within 5 days of infection, with a 79% risk reduction, although it was not statistically significant (<i>p</i> = 0.164). <b><i>Conclusion:</i></b> Patients with MF/SS do not necessarily have worse COVID-19 outcomes compared to the general population.
Discussion(0)
No comments yet. Be the first to comment.